VASOXYL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOXYL is an injectable small-molecule drug approved by GSK in 1949 with an unknown mechanism of action and indication profile. As a legacy NDA product now approaching loss of exclusivity, it represents a mature asset in GSK's portfolio with limited modern clinical development.
LOE Approaching
With LOE approaching and minimal current spending data, this product is likely in managed decline with a small, experienced team focused on compliance and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VASOXYL offers minimal career development opportunities due to its LOE-approaching status and zero linked job postings. Positions on this product are typically maintenance-focused roles handling compliance, operations, and managed decline rather than strategic growth.
Regulatory Affairs SpecialistSupply Chain Manager
Worked on VASOXYL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.